Skip to content
Research Article Open access CC BY 4.0

Positive Outcome in a Pregnancy with Anti-kell Alloimmunization Treated with Intravenous Immunglobulin and Therapeutic Plasma Exchange Despite Persistence of High Titre Antibody: A Case Report

Cinzia Vio, Anna Colpo, Luca Collodel, Piero Marson, Gianluca Gessoni

International Blood Research & Reviews · pp. 1–6 · Published 24 Jun 2024

10.9734/ibrr/2024/v15i3339

Abstract

Background: Few reports have been published about  the current clinical management of anti-Kell alloimmunization in pregnancy; its low frequency of occurrence means that the few long series published have covered an extensive time period in which different treatment approaches have overlapped. The objective of the present paper is to present our experience in the clinical management of a pregnant woman who was positive for the anti-Kell antibody. Materials and Methods: The laboratory follow-up included the weekly measurement of the antibody titre, and identification of the paternal and fetal genotype. The clinical management included TPE and IVIG administration. Obstetric monitoring included ultrasonographic monitoring of the fetus. Case Description:  We report a case of anti-Kell alloimmunization with high antibody titre at first observation.  Testing for fetal DNA circulating in maternal blood confirmed positivity for KEL1 gene. The patient underwent fifteen sessions of TPE after  18 weeks of gestational age, followed by weekly IVIG infusion, which continued until 27 weeks of pregnancy. Anti-Kell titres were measured before and after each TPE session. The patient had no need for IUBT and delivered by cesarean section at 34 weeks of gestational age.  Pregnancy resulted in a live birth with mild HDFN. Discussion: HDFN is a potentially lethal complication of alloimmunization, and IUBT is the standard treatment for severe fetal anemia. TPE and IVIG are two alternative treatment modalities described in the literature to avoid or postpone the need for IUBT transfusion. In the case reported, despite any substantial change in antibody titre, pregnancy resulted in a live birth. This result suggests that the use of TPE and IVIG in alloimmunization during pregnancy could be an effective treatment strategy.

Anti-Kell hemolytic disease of fetus and newborn therapeutic plasma exchange pregnancy

References (16)

  1. 1 Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue [DOI]
  2. 2 The Blood Group Antigen FactsBook [DOI]
  3. 3 Inhibition of Erythroid Progenitor Cells by Anti-Kell Antibodies in Fetal Alloimmune Anemia [DOI]
  4. 4 Kell sensitization in pregnancy [DOI]
  5. 5 Red Blood Cell Alloimmunization in Pregnancy [DOI]
  6. 6 Therapeutic apheresis during pregnancy: A single center experience [DOI]
  7. 7 Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia [DOI]
  8. 8 Management of pregnancies complicated by anti-Kell isoimmunization*1 [DOI]
  9. 9 The outcome of pregnancy in Kell alloimmunisation [DOI]
  10. 10 Prevalence and obstetric outcome of women with red cell antibodies in pregnancy at the Leeds Teaching Hospitals NHS Trust, West Yorkshire, England [DOI]
  11. 11 The prenatal intervention of pregnancy complicated with anti-Kell isoimmunization: a review [DOI]
  12. 12 Red blood cell alloimmunization in Iran: A Comprehensive review of the literature [DOI]
  13. 13 The significance of anti-Kell sensitization in pregnancy [DOI]
  14. 14 Current clinical management of anti-Kell alloimmunization in pregnancy [DOI]
  15. 15 Red Blood Cell Alloantibody Titration - Does the Titration Method Matter? [DOI]
  16. 16 Anti‐Kell in Pregnancy and Hydrops Fetalis [DOI]

Cited by 2

Successful management of severe hemolytic disease of the fetus and newborn (HDFN) due to anti-Kell

Erika Hrastar, I. Bricl, T. Premru-Sršen · Journal of Perinatal Medicine · 2025

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

49

Page views

0

PDF downloads

5

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.